Inaugural initiative of AARP and MedCity News showcases companies and
people delivering cutting-edge healthcare solutions for the 50+ market
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it was selected as
one of the healthcare industry's 50+
Innovation Leaders under an AARP initiative administered by MedCity
News to recognize entrepreneurs, companies, and ideas behind innovative
new products and services for Americans aged 50 and older.
The winners of the inaugural 50+ Innovation Leaders program were
revealed today during the AARP
Innovation@50+ LivePitch event by representatives of MedCity News
and AARP.
NeuroMetrix is applying neurotechnology to address the chronic pain
epidemic with a 100% drug free, wearable technology solution called Quell®.
The FDA cleared device works by stimulating the sensory nerves in the
upper calf, which carry neural pulses to the brain, activating the
body's natural pain blockers. Quell was designed to meet the needs of
people with conditions like arthritis, back pain, leg pain, and nerve
pain, who are looking for better options to manage their pain without
side effects.
"Quell empowers those living with chronic pain to reclaim their life
through advanced technology. Being recognized as a 50+ Innovation Leader
confirms that we are serving the chronic pain community well, and will
continue to provide innovative, alternative options for treatment," said
Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are
always striving to provide solutions for the over 100 million Americans
feeling the effects of chronic pain."
"AARP works to empower people to choose how they live as they age," said
Jeffrey Makowka, AARP's Director of Market Innovation. "We are pleased
to join MedCity News in showcasing entrepreneurs who are driving change
and improvements in the healthcare industry for the more than 100
million Americans aged 50 and older. We congratulate the remarkable
winners who have been recognized by their peers for their innovation
leadership."
In late 2016, MedCity News and AARP issued a call for nominations for
entrepreneurs, investors, companies, and nonprofit collaborations.
Determined by a reader vote, the winners include leaders and companies
offering healthcare delivery, medication management, and smart wearables.
The full list of winners can be seen at medcitynews.com/50-plus-innovation-leaders/.
About AARP
AARP is the nation's largest nonprofit, nonpartisan organization
dedicated to empowering Americans 50 and older to choose how they live
as they age. With nearly 38 million members, and offices in every state,
the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, AARP
works to strengthen communities and advocate for what matters most to
families with a focus on health security, financial stability and
personal fulfillment. AARP also works for individuals in the marketplace
by sparking new solutions and allowing carefully chosen, high-quality
products and services to carry the AARP name. As a trusted source for
news and information, AARP produces the world's largest circulation
publications, AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org
or follow @AARP and @AARPadvocates on social media.
About MedCity News
MedCityNews is the leading online news source for the business of
innovation in healthcare. We offer insight into what's next and what
matters with a mix of breaking news and analysis on startups and
established industry leaders, personalities, policies and the most
important deals. Learn more at www.medcitynews.com
or follow @medcitynews on social media.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT Division
of Health Sciences and Technology in 1996. For more information, please
visit NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170413005105/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
